Search - tctmd.com

Displaying 1 - 20 of 246

Sort: Relevancy | Date

News Daily News

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Yael L. Maxwell

December 15, 2025

News Daily News

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

Yael L. Maxwell

October 24, 2025

News Daily News

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Caitlin E. Cox

October 03, 2025

News Daily News

Risk Factors Present in Nearly All Patients Who Develop CVD

Michael O'Riordan

October 02, 2025

News Daily News

CVD Still the Leading Cause of Death and Disease Globally

Michael O'Riordan

September 24, 2025

News Daily News

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Todd Neale

September 18, 2025

News Daily News

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Michael O'Riordan

August 06, 2025

News Daily News

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Michael O'Riordan

July 31, 2025

News Daily News

Heart Disease Treatment Costs $100 Billion per Year in the US

L.A. McKeown

July 30, 2025

News Daily News

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Todd Neale

July 16, 2025

News Daily News

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

Michael O'Riordan

June 25, 2025

News Daily News

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Yael L. Maxwell

April 16, 2025

News Daily News

Cardiotoxicity Rare With Common GI Chemotherapy

L.A. McKeown

April 15, 2025

News Daily News

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Michael O'Riordan

March 18, 2025

News Daily News

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Michael O'Riordan

March 06, 2025

News Daily News

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Michael O'Riordan

February 05, 2025

News Daily News

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Caitlin E. Cox

February 03, 2025

News Daily News

Aspirin Use for Primary Prevention Declining in US: NHANES

Michael O'Riordan

January 24, 2025

News Daily News

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Todd Neale

December 06, 2024

Advertisement

FDA Approves Lerodalcibep for Adults With Hypercholesterolemia

Semaglutide’s CV Effects Only Partially Tied to Weight Loss: SELECT Analysis

ACC: It’s Time for Clinicians to Address Inflammation in CVD

Risk Factors Present in Nearly All Patients Who Develop CVD

CVD Still the Leading Cause of Death and Disease Globally

Half of Patients Stop Semaglutide for Weight Loss by 1 Year

Inclisiran Gains Indication as Stand-alone Therapy to Reduce LDL Cholesterol

Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT

Heart Disease Treatment Costs $100 Billion per Year in the US

Wider Use of Polypills to Prevent CVD Could Save Millions of Lives by 2050

Weight-Loss Medications Should Be Part of Cardiology’s Arsenal: ACC

High-Sensitivity Troponin Tests Might Aid in Primary Prevention

Cardiotoxicity Rare With Common GI Chemotherapy

Newer Weight-Loss Drugs Not Cost-effective at Current Prices

Less Plaque Progression With CAC-Guided Primary Prevention: CAUGHT-CAD

Elderly ASCVD Patients Benefit From Aggressive LDL-Lowering With Evolocumab

Use of Secondary CVD Prevention Meds Still Meager Worldwide

Aspirin Use for Primary Prevention Declining in US: NHANES

Questions Raised Anew About Aspirin for Secondary Prevention of ASCVD

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content